MOONLAKE IMMUNOTHERAPEUTICS Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $10.00 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2025-02-26
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $10.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2024-12-31 | $10.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |